Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.

BioRxiv : the Preprint Server for Biology
Seth J ZostJames E Crowe

Abstract

Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date 1,2 . In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes based on their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of new antibody discovery methodologies.

Citations

Jun 28, 2020·Journal of Virology·John P Moore, P J Klasse
Aug 18, 2020·Journal of Immunology Research·Andrés NoéEleanor Barnes
Jul 15, 2020·Science·Meng YuanIan A Wilson
Jan 5, 2021·Frontiers in Immunology·Yannick GalipeauMarc-André Langlois
Jan 16, 2021·Proceedings of the National Academy of Sciences of the United States of America·Varun SasisekharanUma Narayanasami
Jun 13, 2021·Signal Transduction and Targeted Therapy·Qianqian ZhangFei Yu
Sep 2, 2020·ACS Central Science·Ariel H ThamesMichael C Jewett

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
ELISA
electron microscopy
flow cytometry
RNAseq
single-cell sequencing

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.